✦ LIBER ✦

Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate

✍ Scribed by Franca Pompetti; Antonio Spadano; Antonella Sau; Antonio Mennucci; Rosa Russo; Virginia Catinella; Paolo Guanciali Franchi; Giuseppe Calabrese; Giandomenico Palka; Giuseppe Fioritoni; Antonio Iacone

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 363 KB
Volume: 31
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2006.05.021

No coin nor oath required. For personal study only.

✦ Synopsis

BCR/ABL-positive acute myeloid leukemia (AML) is a rare disease, characterized by a poor prognosis, with resistance to induction chemotherapy and frequent relapses in responsive patients. Here we report a case of BCR/ABL-positive AML-M6 who, after relapse, was treated with Imatinib Mesylate (600 mg/die) and within 4 months achieved a cytogenetic and molecular complete response. After more than 4 years of continuous Imatinib therapy, nested RT-PCR for BCR/ABL is persistently negative. The case reported shows that the response obtained with Imatinib Mesylate in BCR/ABL-positive AML may be long lasting, offering a chance of successful treatment for this poor prognosis group of patients.

📜 SIMILAR VOLUMES

Long-term remission in a patient with BC

Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib

✍ Enrico Schalk; Silke Neum; Sandra Kranz; Katrin Scheinpflug; Martin Mohren 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Long-term remission with imatinib mesyla

Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma

✍ Mohamed S. Ahmed; Steven H. Kroft; Nancy B. Davis; David M. King; Yee Chung Chen 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 624 KB

Philadelphia chromosome-positive acute m

Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): A report with IM plasma concentration and bcr-abl transcripts

✍ Toshinori Kondo; Taizo Tasaka; Fuminori Sano; Kimiko Matsuda; Yasutaka Kubo; Yos 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 159 KB

We studied the efficacy and pharmacokinetics of imatinib mesylate (IM) and bcr-abl expression in a Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) patient, a rare disease with a poor prognosis. Although sufficient IM trough concentrations were maintained, bcr-abl transcripts revea